Gut Hormones and Obesity Management: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies

Abstract

Obesity, a complex multifactorial disease, is increasingly recognized as a global epidemic with major health and economic consequences. Gut hormones are pivotal regulators of appetite, energy balance, and glucose homeostasis, providing a mechanistic basis for novel therapeutic strategies in obesity management. This review synthesizes recent evidence on the physiological and pathophysiological roles of gut hormones in obesity, examines their clinical relevance, and discusses current and emerging therapeutic interventions targeting these pathways. The integration of gut hormone modulation into clinical practice holds significant promise for improving patient outcomes and addressing the obesity epidemic.

Introduction

Obesity is a chronic, relapsing disease characterized by excessive adiposity, leading to increased morbidity and mortality. The last decade has witnessed a paradigm shift in understanding obesity, moving beyond simplistic energy imbalance models toward recognizing the intricate neurohormonal regulation of appetite and metabolism. Gut hormones, secreted primarily by enteroendocrine cells in response to nutrient ingestion, play a central role in satiety, hunger, and energy expenditure. Understanding these mechanisms is essential for clinicians seeking effective, mechanism-based obesity interventions.

Epidemiology / Disease Burden

Globally, obesity rates have tripled since 1975, with over 650 million adults classified as obese according to WHO estimates. The prevalence is particularly high in developed nations but is rising rapidly in low- and middle-income countries. Obesity is strongly associated with type 2 diabetes, cardiovascular disease, certain cancers, and reduced life expectancy. The economic impact includes increased healthcare expenditure and reduced workforce productivity, underscoring the urgent need for effective prevention and management strategies.

Pathophysiology

The gastrointestinal tract acts as both a digestive and an endocrine organ, releasing a range of hormones in response to food intake. Key gut hormones implicated in obesity include ghrelin (orexigenic), and the anorexigenic peptides: glucagon-like peptide-1 (GLP-1), peptide YY (PYY), cholecystokinin (CCK), and oxyntomodulin. Ghrelin, secreted mainly from the stomach, stimulates appetite and food intake. In contrast, GLP-1, PYY, and CCK, released from the small intestine and colon, promote satiety and reduce caloric intake. Dysregulation of these hormonal signals, often driven by genetic and environmental factors, contributes to the development and maintenance of obesity. Altered secretion, receptor sensitivity, and signal integration within the hypothalamus and brainstem form the mechanistic basis for gut hormone-targeted therapies.

Risk Factors

Multiple factors influence gut hormone dynamics and obesity risk. Genetic polymorphisms affecting hormone synthesis, secretion, or receptor function contribute to inter-individual susceptibility. Dietary composition, particularly high-fat and high-sugar diets, can blunt the anorexigenic response and promote hyperphagia. Other risk factors include sedentary lifestyle, psychosocial stress, sleep disturbances, and certain medications that impact gut-brain signaling. Bariatric surgery, while effective for weight loss, also alters gut hormone profiles, highlighting their central role in energy homeostasis.

Clinical Features

Obesity manifests clinically as excessive adiposity, typically assessed by body mass index (BMI), waist circumference, and body composition analysis. Patients may present with comorbidities such as insulin resistance, dyslipidemia, hypertension, non-alcoholic fatty liver disease, and obstructive sleep apnea. Altered gut hormone profiles can manifest as persistent hunger, reduced satiety, and difficulty achieving or maintaining weight loss. Recognizing these features can guide targeted assessment and personalized management strategies.

Diagnosis

The diagnosis of obesity is primarily anthropometric, with BMI ≥30 kg/m2 serving as a clinical threshold. Assessment should include evaluation for obesity-related comorbidities and secondary causes. Measurement of fasting and postprandial gut hormone levels, while not routinely performed, is increasingly utilized in research settings to phenotype patients and predict response to interventions. Emerging biomarkers and functional assays may enhance diagnostic precision in the future.

Treatment & Management

Lifestyle modification, encompassing dietary intervention, physical activity, and behavioral support, remains the cornerstone of obesity management. However, long-term success is limited by physiological adaptations, including compensatory changes in gut hormone secretion that promote weight regain. Pharmacological therapies targeting gut hormone pathways have gained prominence. GLP-1 receptor agonists (e.g., liraglutide, semaglutide) enhance satiety and reduce energy intake, demonstrating significant efficacy in weight reduction and cardiometabolic risk improvement. Combination therapies, such as GLP-1/GIP dual agonists, are under investigation. Bariatric surgery (e.g., Roux-en-Y gastric bypass, sleeve gastrectomy) induces profound and sustained weight loss in part through modulation of gut hormone profiles, particularly increased GLP-1 and PYY secretion and decreased ghrelin levels.

Recent Advances / Emerging Therapies

Recent years have seen major advances in gut hormone-based therapeutics. The approval of higher-dose GLP-1 analogues and the development of dual and triple agonists (targeting GLP-1, GIP, and glucagon receptors) represent significant steps forward. Oral small-molecule modulators of gut hormone receptors are in clinical trials, aiming to improve convenience and adherence. Personalized medicine approaches, including genotyping and gut hormone profiling, may optimize therapy selection in the future. Novel endoscopic procedures and microbiome-based interventions also show promise in modulating gut hormone secretion and appetite regulation.

Guideline Recommendations

Major clinical guidelines, including those from the Endocrine Society and the American Association of Clinical Endocrinologists, recommend considering pharmacological therapy with GLP-1 receptor agonists in patients with BMI ≥30 kg/m2 or ≥27 kg/m2 with comorbidities when lifestyle modification alone is insufficient. Bariatric surgery is indicated for severe obesity or failure of conservative therapy, with attention to preoperative assessment and long-term follow-up. Integrated, multidisciplinary care is emphasized, and emerging therapies should be considered as evidence and regulatory approvals evolve.

Conclusion

Gut hormones are central to the regulation of appetite, energy balance, and metabolism, offering compelling targets for obesity management. Advances in pharmacotherapy and surgical techniques leveraging these pathways have transformed clinical practice, enabling more effective and sustainable weight loss. Continued research into gut hormone physiology, genetics, and therapeutic modulation holds promise for addressing the growing global burden of obesity and its complications. Clinicians should remain abreast of evolving evidence to integrate gut hormone-based interventions into comprehensive, patient-centered obesity care.